Fundraising Fox
Skylark Bio
Cambridge, US · Founded 2021 · Delaware corporation · 20 employees on LinkedIn · 2 known investors
Find your way into Skylark Bio
Sign up to see every warm intro you have to Skylark Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Skylark Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Skylark Bio develops precision-targeted, locally delivered AAV gene therapies for single-gene disorders, starting with genetic causes of hearing loss and extending toward central nervous system conditions. Spun out of research at Harvard Medical School and Massachusetts General Hospital, the company builds a gene therapy platform aimed at durable benefit from a single treatment for patients with genetically defined diseases.
Also known as Skylark Bio, Inc.
Founders & leadership
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$40.9M disclosed across 1 of 2 rounds · 2022–2026
▶$40.9MraisedApr 2024 · 2 investors · BiotechnologyRule 506(b)
- Steve GillisDirector
- Giampiero De LucaDirector
- Jodi A. CookExecutive Officer, Director
- Will McLeanExecutive Officer
- Offering amount
- $40.9M
- Amount sold
- $40.9M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Skylark Bio, Inc. is a gene therapy company working on treatments that address genetic causes of hearing impairment, with the stated aim of improving patient outcomes and quality of life [0]. Company profiles describe it as founded in 2021 and based in Massachusetts, United States, with fewer than 10 employees as of a February 2026 profile update [1]. It is characterized in industry coverage as a Boston-based gene therapy developer [1].
The company has been described as preclinical, with its chief executive characterized as "the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness" [4]. As of January 2026, an investor in the company stated that Skylark was entering a clinical trial enrolling 10 children with an experimental medicine for pediatric hearing loss [1].
Business model
Skylark Bio is a therapeutics developer funded by venture capital rather than by product sales; the available sources describe research and development of gene therapy candidates and progression toward clinical testing, with no disclosed commercial products or revenue [0][1][4].
Traction
As of January 2026, the company was reported to be entering a 10-child clinical trial of an experimental medicine for pediatric hearing loss, and its website stated that ARCH Venture Partners had led $60 million in funding for the company [1]. A drug-database profile notes fewer than 10 employees and no listed medical patents associated with the company as of February 2026 [1].
Latest developments
In January 2026, Israel-based Arkin Capital disclosed that it had participated in a financing for Skylark Bio as the first investment from its $100 million Arkin Bio Ventures III fund, and stated that the company was entering a 10-child clinical trial for pediatric hearing loss; the same report cited the company's website as saying ARCH Venture Partners had led $60 million in funding [1].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Skylark Bio is an early-stage, seed-stage-classified biotech in the biotech and life sciences sector [0]. A startup directory lists Skyhawk Therapeutics, Dyne Therapeutics, Siren Bio, Dyno Therapeutics, and Encoded Therapeutics as similar companies [0].
Technology
The company develops gene therapies targeting the genetic causes of hearing impairment [0], with a lead experimental medicine for pediatric hearing loss described as entering a small clinical trial in children [1].
Go-to-market
Patients with genetic hearing impairment, with the initial clinical focus on children with pediatric hearing loss [0][1][4].
Geography
Headquartered in Massachusetts, United States, and described in press coverage as Boston-based [1].
History
Company profiles date Skylark Bio's founding to 2021 in Massachusetts [1]. Jodi Cook, PhD, serves as President and CEO; she previously was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics and founding Chief Operating Officer of Agilis Biotherapeutics, where she oversaw its $1 billion acquisition, and she holds a PhD from Arizona State University, a Master's in Audiology from the University of South Carolina, and a BA from Loyola University Maryland, with a fellowship at Johns Hopkins Medical School [4].
Risks & controversies
The sources note the company is very small (fewer than 10 employees) and at an early development stage entering a small first clinical trial, and its CEO has publicly described operating a biotech in a challenging funding climate [1][4]. No controversies are reported in the available sources.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsArkin Capital, an Israel-based investor, said it took part in a financing for Boston gene therapy developer Skylark Bio; the investment was described as the first from its newly closed $100 million Arkin Bio Ventures III fund, which writes roughly $10 million seed and Series A checks.
An investor stated that Skylark Bio is entering a clinical trial enrolling 10 children with an experimental medicine for pediatric hearing loss.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 5
primary sources listed
- Skylark Bio — Biotech & Life Sciencesf4.fund · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Skylark Bio do?
- Boston-area biotech developing gene therapies for genetic causes of pediatric hearing loss.
- Who are Skylark Bio's investors?
- Skylark Bio's investors include ARCH Venture Partners, Arkin Capital.
- How much funding has Skylark Bio raised?
- Skylark Bio has disclosed $40.9M raised across 1 of its 2 known rounds.
- Where is Skylark Bio headquartered?
- Skylark Bio is headquartered in Cambridge, US.